Coprimary endpoints. (A) Primary lymphadenopathy endpoint: least square mean of the change from baseline at D85 in the log₁₀-transformed sum of product diameters of the index lymph node lesions in the PD analysis set (leniolisib, n = 18; placebo, n = 8). One patient in the leniolisib group was excluded because of complete resolution of lesions by D85 (0 mm), therefore the log₁₀ transformation could not be computed. Compared with placebo, leniolisib reduced lymphadenopathy (P = .0006). (B) Primary naïve B-cell endpoint: least square mean of the change from baseline at D85 in the percentage of naïve B cells (CD19⁺CD27^-CD10^-) out of total B CD19⁺ cells in the B-PD analysis set (leniolisib, n = 8; placebo, n = 5). Compared with placebo, leniolisib increased naïve B-cell levels (P = .0002). Error bars are SEM. ∗∗∗P ≤ .001. CFB, change from baseline; SEM, standard error of mean.